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Melanoeytes and melanoma cells are known to possess receptors for melanoeyte stimulating hormone (MSH). A eDNA clone, designated l ID, 
has b~.~n isolated from human melanoma cells and encodes a MSH receptor. The cloned eDNA encodes a 317 amino acid protein with 
transmembrane topography characteristics of a G-protein.coupled receptor, bat it does not show striking similarity to already pablish~ sequences 
of other G-protein-coupl~ receptors. When 11D eDNA is expressed in COS-7 cells, it binds an Z~l-labelled MSH analogue (NDP-MSH) in a 
Sl~Cifie manner. The bound ligand could be displaced by melanotropie peptides, a~-MSH, fl.MSH, 7-MSH and ACTH (adrenoeonieotropie 
hormone), but not by the non-melanotropie ~ptid¢,/3-endorphine. Thisis the first report of the cloning of a receptor geae of the melanotropin 
receptor family. 
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1. INTRODUCTION 
Melanocyte stimulating hormone (MSH) is a strong 
stimulator of pigment cells, modulating the colour 
change in animals [1]. In humans injections of g-MSH 
induces darkening of the skin through melanogenesis 
[2]. Many cultured melanoma cell lines undertake 
melanogenesis through the formation of cyclic AMP [3], 
which in turn activates tyrosinase, the rate-limiting en- 
zyme of melanin formation [4]. Besides the pigmenting 
effect, MSH has also been shown to act as a neurotrans- 
mitter in the central nervous system [5], as an endocrine 
stimulant [6] and as a modulator of immune inflamma- 
tory responses [7]. The hormone is considered a poten- 
tial tool in the diagnosis and therapy of melanoma as 
it has been used in conjugation with cytotoxin [8] ~r:,~ 
cytotoxic T-cells [9] for killing melanoma cells by recog- 
nizing their MSH receptors. Recently it has been shown 
that MSH can increase intracellular calcium and acti- 
vate protein kinase C [10]. Two other G-protein-cou- 
pled receptors, namely the aab-adrenergic receptor and 
serotonin receptor, which are also coupled through the 
above mentioned second messenger system, have been 
shown to be protooncogenic [11,12]. In the following 
report we describe for the first time the primary struc- 
ture of the MSH receptor. 
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2. MATERIALS AND METHODS 
2. I. Polyznera~'e chain reaction 
The oligonucleotide primers were designed by careful examination 
of the .~'x-lnenee homologies in membrane-spanning se ments, 3 and 
6, of the earlier clont.M G-protein-couple¢l receptors. The design ofthe 
primers was not inclined towards any one receptor or any one class 
of the receptors. The primers ware degenerate (redundant, -- 8 for the 
primer from segment 3 and 32 for the primer from segment 6), and 
also had an inert ntmleotid¢, deoxyinosine, atplaces which otherwise 
would have become highly degenerato. Primers w~r~ synthesized with 
EcoRI {segment 3) and BamHl (segment 6) linkers at the 5" ends to 
facilitate the cloning. The primer sequences were: (i) 5'- 
G GGAA'ITCTGTG ffC)G(TC)IATCICI(GC)TGGACCGGTA 
(from segment 3); (ii) 5"-GGGGATCCGAAGAAGQGI(ACXGA)- 
CCAGCAGA(GC)I(AGXCT)GAA (from segm¢nt 6) 
1/zg of human genomie DNA was subjected to PeR using the above 
described primers. The PCR was done in a final volume of 50,ul and 
~:ontained I/zg of human genomi¢ DNA, 10 mM Tris-HCI, pH 8.3, 
50 mM KCI, 1.5 mM MgCi:, 0.001% gelatin, 200/~M ofcaeh deoxyan- 
eleotide, i/~M of each primer and | U of the enzyme, Taq DNA 
polymerase (Perkin Elmer Cettts, USA). The PCR thermal profile 
used was 93°C for 60 s, 55"C for 40 s and 72"C for 60 s for a total 
of 25 cycles, using a thermal Cycler (Hybaid, UK). 
10% of the reaction was analy~ed by agaro~¢ gel ¢lcetrophon:sis. 
One product was observed at the 372 bp position which was cloned 
into the pGEMTr£(+) vector (Promega Corp., USA) and the resulting 
plasmid, termed OF.A, was sequenced truing the chain-termination 
method [I 3]. 
2.2. Northern blot analysis of the GE4 mRNA 
Poly(A) ~ RNA was prepared from the following tissues: brain, 
thymus, parathyroid gland, parotid ~land, salivary gland, adrenal 
gland, testis, liver, lung, heart, spleen, skeletal muscle, intestine, colon 
and WM 266.4 human melanoma cells (ATCC # CKL 1676). 10/~g 
of poly(A) ÷ RNA was suhj~tcd to el~trophoresis through a 0.8% 
agarose-formaidehyde gel. The RNA v~as then blotted onto a 
GeneScrecn membrane (New Enuland Nuclear. USA). The hybridiza- 
tion was done in a solution containing 50% formamide, $ × SSC, 5 × 
Denhardt's solution, 0.1% SDS, l0 mM sodium phosphate, pH 7.0, 
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10 mM EDTA. 0.1 mg/ml denatured calf thymus DNA and '~:P. 
labelled GE4 DNA probe. The GE4 DNA was labelled with .~2p using 
a commercial muhiprime kit (Amersham, UK). The membrane was 
left in the hybridization solution for 12 h at 42°C. The membrane was 
then washed in a solution of 0.1 x SSC and 0.1% SDS at 60°C for 30 
rain, air dried and then exposed to autoradiographie film for 16 h (see 
Fi~. I). 
2.3. Constnwtion and screening of the eDNA library fi'om the human 
melanoma cells 
The WM 266-4 cells were obtained from ATCC, Bethesda, USA, 
and grown in the medium as advised b:¢ ATCC. Poly(A) + RNA from 
these cells was made using the fast-track mRNA isolation kit (In- 
vitrogen Corp., USA). A random primed eDNA library was con- 
structed in lambda 8tl I vector (Amersham, UK) from poly(A)* RNA 
of WM 266.4 melanoma cells. Approaimately, 7 x l0 s plaques from 
the unamplified library were screened with 3-'P.labelled GE4 probe. 
H~'bridization was done in a buffer (6 × SSC, 5 x Denhardt's solution, 
10 mM sodium phosphate pH 7.0, I mM EDTA, 0.5% SDS and O.l 
mg/ml denatured salmon testis DNA) at 60°C for 12 h. Filters were 
then washed at 65°C in a solution of 0.1 x SSC and 0.1% SDS for 20 
min, and exposed to X-ray film for 24 h. Positive plaques were picked 
and alter repeating the screening two more times a positive plaque, 
designated 11D, was isolated. Both strands of the entire coding region 
were seqaenc~:.~ b>' the chain.termination method [13]. 
2.4. Functional expression of the lID eDNA 
The cDNA from clone I 1D was inserted between EcoRl and Nail 
sites of peDNAI vector (lnvitrogen, USA). COS-7 cells were grown 
in Dalbeccu's modified Eagle's rn~dit, Alwith 8% foetal calf serum and 
non-es:~ential amino acids. 80% confluent cultures were transfeeted 
with 1 pg DNA and 40/.tg lipofectin (BRL, USA) in serum-free 
medium. 5 h after transfection, the -~erum-containing medium was 
replaced, and cells were cultivated for 20 h. Cells were then scraped 
off, centrifuged, resuspended in serura-containing medium, plated on 
48 well plates, and allowed to grow lbr 24 h. The cells were then 
washed with 0.3 ml of binding buffer (minimum essential medium with 
Earle's salts, 25 mM HEPES, pH 7.0, 0.2% bovine serum albumin, ! 
mM 1,10-phenanthroline, 0.5 mg per litre leapcptin and 200 mg ~r  
litre bacitracin) and then incubated at 37°C for 2 h with 0.3 ml binding 
buffer containing 24,000 cpm of [~'~SI]N DP-MSH and the appropriate 
concentration of unlabclled peptides. NDP-MSH was labelled with 
:-sI and purified as described before [14], to a Sl~Cilie activity of 
8.6 ×10 *Ci per reel. The plates were then put on ice, the cells washed 
with 0.3 ml of ice-cold binding buffer, and detached from plates with 
0.3 ml of 0.1 N NaOH, Radioactivity was counted and data analysed 
by a iterative, non-linear curve fitting programme suitable for radioli- 
sand binding analysis. 
3. RESULTS AND DISCUSSION 
PeR primers were designed based on the consensus 
sequences of transmembrane segments 3 and 6 of 
known G-protein-coupled receptors. Primers were used 
to perform PCR on human genomic DNA, as man2~ 
G-protein-coupled receptors are known to be intron- 
less. One product, designated GE4, was obtained which 
was cloned into pGEM7Zf(-+) vector and sequenced to 
completion. It was found to contain a 372 nucleotide- 
long sequence, showing G-protein coupled-receptor 
characteristics. This DNA was then used as a probe to 
screen tissues for its expression using Northern blot 
analysis (Fig. 1). A specific RNA band was seen only 
in the melanoma cell line, WM 266-4, poly(A)* sample. 
This prompted us to screen a eDNA library from a WM 
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Fig. 1. Northern blot analysis of the tissue distribution of GFA 
mRNA. Poly(A)* RNA (10/zg) from different tissues, namely, brain, 
thymus, parathyroid gland, parotid gland, salivary gland, adrenal 
gland, testis, liver, lung, heart, spleen, skeletal muscle, intestine, colon 
and WM 266.4 melanoma cells was subj~ted to electrophoresis 
through a 0.8% agarose-formaldehyde gel, blotted onto GeneSereen 
(New England Nuclear, USA) and hybridized to a ~-P-labeled GE4 
probe. Here, only the WM 266.4 lane is shown as all the other tissues 
were completely negative. Positions for 28 S and 18 S ribosomal RXNA 
am marked with arrows. 
266-4 cell line with the GE4 probe. One clone, desig- 
nated l iD,  was isolated with an insert of 1,800 bp, 
containing a long open reading frame and an entire 
coding sequence (Fig. 2). The MSH receptor contained 
seven hydrophobic segments of amino acids, a charac- 
teristic of G-protein-coupled receptors, which are pre- 
dicted to span the cell membrane seven times. 
The 951 bp coding sequence begins with ACTATGG 
which is in agreement with the Kozak consensus e- 
quence for translation initiation sites [15]. The entire 
protein consists of 317 amino acids with a total molecu- 
lar weight of 34,795 Da, without considering any post- 
translational modifications. The N-terminal region con- 
tains two potential N-glycosylation sites at amino acid 
positions 15 and 29. The second cytoplasmic loop and 
COOH-terminal region (amino acids 142-145, 151-154 
and 306-308) contain consensus sequences for cAMP- 
dependent protein kinase recognition [16]. The. third 
cytoplasmic loop consists of 30 amino acids, which is 
similar in size to other G-protein-coupled peptide recep- 
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-1~ G~A G~ GGT GTG AGG 
-120 GGC ATG GGG GAC ACC 
-';2 GAC ArC TGG AGO ~GA 
I 
-24 CC~ TCC TC~ TTC CtO 
9 ~xg L~u Leu GXV $~c 
24 ,P,=4~  ff?~ 0GC q'C~ 
25 G1 y L~U ~a Ala A~n 
72 C~G CTG C~'T GCC N%C 
C/.A CAT ~ GGG GTG CC~ AGA TG~ A%S ~ C~A -121 
CAA GGC CCC C£G GCA GCA CCA TGA ACT ASG CAG -?3 
~ ACT ~'~'G C~3G ACe TGG AG~ CCT CCA ,~G ACT -25 
t'Je~; Ale V~I Gin G1¥ ~ Gln A~g 0 
GAC. AG~ ACT ATG GeT GTG CAG C.~A TCC C.A~ A~,~ 23 
L~J A~n Sot ~hc Pro T~r Ala ZIo Pro Gln Leu 24 
CTC A~C TCC ACC CCC ACA GCC ,%TC CCC CA~ CTG 91 
Gin ?he Gly A.l.a Ace CMS Le~ GIu Val Se~ ~'o  40 
CA~ ACA C~g~ GC¢ C, GG ~ CT~ C, N3 GTG ~ ~ 119 
41 S<~r A~p GI¥ L.QU, E,Tm ~u Set L.au G.Ly ~u VaX Set' ~u  V-~ Glu ~ 56 
220 ~ GAC GC-G CTC TTC C¢C~6C~'¢G C,C~G CTG GTG B~,LT'tO ~ ~ ~ 167 
5? ,r~l~ ~U V¢1. V~Z ,M.a ~ Z1¢ RJ, a by0 A~n ,%=~1 ~ I.¢u H is  Set l~ro "t2 
16~ ()CG C'?O G ' ~  GCC ~,CCI M'~ GCC ~ ~ CC~ RA¢ CTG ~ TC.A CC¢ 215 
ZZ 
216 a'l~ TAC ~ X"J['CJVm. ~ TC, C C~G C-,CC 'F£G_"teG C~C CTG ~ GTG ACC 263 
f19 GZy SO~ ASh Val L~u GLU T~c Ala Val 11o LOU' LOQ L~U GZu Ala 011' 104 
2~4 _¢#~AC~_ ~_~_q '~q_QA~ AC~ q¢~ ~'TC AT~ C'fC C~G CTG G&G GCC ~ 311 
~.05 Ala L~u Val A/a A~O Ala Ala Wal ~u Gln Gln L~ iAu'~ nan va l  x l~  120 
312 ~ ~ G"£G GCC CGG ~ ~ GTG ¢'I"3 C.,AO ~ CT~ I~ ,,",AT GTC A"Ft 359 
121 ,'~,'~9 Va~- - :q~'hr  ey~ SO: g~Y'~¢c he~ Sz:  Set  ~ Cya Phe l~u  S ly  13~ 
408 ~ GAC CGC TAC ATC TCC ATe TTC ~C GCA CTG C~C TAC 4S5 
153 H~.~ S~c x lo  va l  The [~%"Pro ,~r~j A,m m:~ ~r~ ~-~0 va~. Aza ~a x~.o I ~'~ 
456 C.~C AC, C ,~c  ~ AC~ [~ COG eGG GC~ CG~ C.C4~ ~ ~ C,~ ~ ATC 503 
169 "r~rp Val Ala so~ Val Val Ph~ Sot  TI~c Leu Pho Xl~ Alt t iT~¢ Ty= ,'~sp 184 
504 TGG GTG GCC AGT~ (~PC TTC AGC A~'~ CTC ,TTC ATC, C~]TA~ TAC (~AC 551 
V 
Z~5 Hlfl Val Ala Val ~u LO~- C~S" ~ Val Va ~ - ~hO ~hW LQU Ala M~t L~ 200 
552 C.AC f f~  C.~¢ G"T¢ ~ CI"G TGC ~ G'IG 6'TC T~' I~PL¢ ' J~  C-C? ATG ~T~ 599 
~01 val L~u ;4~ Ala Val ~u ~r  Val H~Hec 1~u AI~ A=g Ala Cy~ Gln 216 
600 G'[G CTC Aq~ C~C gl~ CTG TAC ~ CAC ATG CTG GCC CGG ~ TGC CA~ ~47 
217 1t5.11 Al~t Gln ~Iy ~lo Ala ~xg LQU Hi~ LMS AX~ Gln Ar~ p~O Val Bi~ 232 
648 CAC C~C CA~ C, GC ATC GCC eGG CTC C~ AAG AGG CAG CGC COG GTC CAC ~5 
233 Gln GIF Phs GI7 L0u LyS GIV AI& Val Th~ I .~u[~'~ '~ L~O Leu Gly 240 
~9~ CAG C.GC "..~T ~ ~ ~ GGC ~ ~ A.CC C"~CI~CC A~C C'5%S CT~ ~C ?43 
VZ 
2a-§ "fl-~-i~-1~h~-h¢~ Cys 2'rp GZF ~co Ph~ Phu L~U His /.,ou ' ~  264 
?4q ATT TT: ~C CTC TGC~I~G¢~C TTC ~PC CT~ CAT CTC A~A_L'T~_ATC~ 9~1 
~65 QAI L~u C~s PrOIGIu Hi~ PrO The Cys GI~ C~'~ ~IQI'P~ A L~B ~n Phe 280 
792 ~ C4~ CAC CCC ACO TGC G~C TGC A T C ~  839 
V2Z 
20~. "~- -n - i~ , -~h~:~-g~~, ,u  ~a x~.¢ ¢:t~ ~n AJ.a r,~o x~.o .~1~ p~o ~..~u 296 
~40 2wAC CTC ~ CTC~CC, ~C ATC ~TC TC~ AAT C~CC ATC ATe GAC CCC CTC ~?  
297 Ila Tyr Ala F~e] His 5~r Gln Glu Lau A~ ~g ~r  L~U Lys Glu Val 312 
~8~ ~ ~ AC..C C.AS ~ CTC CC, C ~ ACG CTC ~ GI~ GTG 935 
313 L~u Thr C~S Sec  '.~rp L"~. 32fl 
~36 CT~ ACA T~C TCC TGG TGA ~ CGG TGC ACG CGC TTT AAG TGT OCT GGG ~03 
~4 CAG AG~ GAG GTG gl~ ATA TTG TGT ~ CTG GTT OCT GTG ¢GA CCC TGG 1031 
1032 GC~ GT'? CC? TAC CTC CCT GGT C¢C CGT ~ TCA ~ ~ AT(; ~ TAA 1079 
10B0 ATG ATC TC~ GAA AGT GTT GAA G 1101 
Fig. 2. Nueleotide and predicted amino acid sequence of human MfiH 
receptor. Transmembrane segments (enclosed within boxes) were de- 
termined by hydropathy analysis a~ording to Kyte and Doolittle [22]. 
The glycosylation sites (¢). possible phosphorylation sites (*) and 
possible palmitylation site (§) are marked. 
tors. Previously it has been shown that the MSH recep- 
tor is positively coupled to adenylate cyclase [3], an 
effect likely to be mediated by the stimulatory guanine 
nucleotide regulatory proteins, G,. Amino acid cysteine, 
corresponding to the Cys-315 in the COOH-terminal 
region of the cloned MSH receptor, is conserved in 
other Gccoupled receptors, where it is implicated to 
have a role in the covalent attachment to palmitic acid 
[n,18]. 
It is possible to classify G-protein-coupled receptors, 
based on similar amino acid sequences, into subfamilies, 
such as into the mu~arinic, ad,'energic, dopaminergic, 
histaminergic, serotoninergic and tachykinin receptor 
families [19]. Different receptor molecules in an individ- 
100| o ~ r ^ ~ . ,, / I . I  i . 
80 
• 8 8o 
Competitor Iog(nM) 
Fig. 3. Relative potencies o~" melanotropins forinhibitin8 [~I]NDP- 
MSH bindin$ to COS-7 ¢¢11s transFccted with MSH receptor eDNA. 
Shown are competition curves for non-labdlod NDP-MSH (I). ~- 
MSH (e), ACTH (1-39) (r~),,8.MSH (A), 7-MSH (v). ACrH (4-10) 
(o) and ,8.-endorphin (a). Each point repres)am the mean of quadru- 
plicate determinations. Non-spe, cifi¢ binding was less than 8% of the 
total binding. 
ual subfamily have similar primary structure, showing 
more than 60--75% homology in the seven transmem- 
brane segments. The cloned MSH r~cptor nucleotide 
sequence and the predicted amino acid sequence did not 
show significant homology to any of the other se- 
quences in the EMBL and SwissProt databases. The 
MSH receptor thus seems to belong to a new subfamily 
among the G-promin-coupled receptors. 
To prove that the clone, I 1D, codes for human MSH 
receptor, it was inserted into a pcDNA1 vector and 
expressed in COS-7 ~lls. Transfected COS-7 cells wore 
then analysed by radioligand binding. An MSH ana- 
logue, NDP-MSH, was chosen as the radioligand be- 
cause of its resistance to chemical and enzymatic degra- 
dation and because of  its reported high affinity for na- 
tive MSH reo~ptors [3,14]. A series of POMC (pro- 
opiomelanocortin)-derived peptides howed ifferent!al 
potencies in inhibiting [t~I]NDP-MSH binding to l lD-  
transfected COS-7 cells (Fig. 3). The potency order was 
NDP-MSH (K~ = 23 _ 0.S pM) > 0~-MSH (El = 92 _ 19 
pM) > ACTH(1-39) (K~ = 170 +_. 37 pM) > fl-MSH (Ki 
= 449 _ 74 pM) > 7-MSH (Ki = 1,010 _ 200 pM). 
ACTH (4-10) (adrenocorticotropi¢ hormone) showed 
very low binding affinity (K~ = 22,400 + 7,200 pM), 
whereas the non-melanotropic POMC peptide, p-cn- 
dorphin, showed no affinity for the expressed MSH 
receptor. These data arc in close agreement with the 
affinities reported earlier for MSH receptors on several 
melanoma cell lines [3,20]. The high affinity of 
ACTH(1-39) for the MSH r~ptor  can be attributed to 
the fact that the first 13 amino acids in the ACTH(l-39) 
molecule makes up the 0~-MSH molecule [21], as they 
are produced from the same POMC v,, , . ,v, .v-, , , . -" '  . . . .  ,;.4,1 h,,,..., h,,.~ 
alternative cleavage [21]. It has nlso been shown that the 
MSH receptor on melanoma cells recognizes different 
419 
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forms of  the ACTH molecule with high affinity, in some 
cases an even higher aff inity than ~z-MSH itself [20]. 
In summary ,  we have c loned a human MSH receptor  
eDNA which shows structural  propert ies of  a G-pro -  
tein-coupled receptor.  When the MSH receptor eDNA 
is expressed in an eukaryot ic  system, it displays b inding 
propert ies fo r  melanotrop i¢  hormones  as expected for 
a nativo MSH receptor,  
Acknowledgements: Supported by the Swedish National Board for 
Technical Development (89-02211P). 
REFERENCES 
[l] Lerner, A.B., Moellmann, G., Varga, J.M., Halaban, R. and 
Pawelek, .I. (1989) Cell Prelif'. 6, 187-197. 
[2] Leviae, N., $heftel, S.N., Eytan, T., Dorr, R.T., Hadley, M., 
Weinrach, J.C., Ertl, G.A., Toth, K., McGee, D. and Hruby, V.J. 
(1991) J. Am. Med. Assoc. 266, 2730-2736. 
[3] Tatro, J.B., Entwistl¢, M.L., Lester, B.R. and geichiln, S. (1990) 
Cancer ges. 50, 1237-1242. 
[4] Halaban, g., Pomerantz, S.H., Marshall, S., Lambert, D.T. and 
Lcrncr, A.B. (1983) J. Cell Biol. 97, 480-488. 
[5] O'Donohue, T.L. and Dorsa, D.M. (1982) Peptides 3, 353-395. 
[6] Reid, R,L., Ling, N. and Yen, S.$.C. 0984) J. Clin. Endogrinol. 
Mctab. 58, 773-777. 
[7] Cannon, J.G., Tatro, J.B., Rcichlin, S. and Dinarello, C.A. (1986) 
J. Immunol. 127, 2232-2236. 
[8] Murphy, J.R., Bishai, W., Borowski, M., Miyaaoham, A., Boyd, 
J. and Nagl¢, S. (1986) Pro¢. Natl, Ac, ad. S~i. USA 83, 8258-~262. 
[9] Liu, M,A., Nussbaum, $,R. and Eisen, H.N. 0988) S¢ica¢¢ 239, 
395-398. 
[10] ButTey, J., Thody, AJ., Bl¢chcn, S.S. and MacNcil, S. (1992) J. 
Endocriaol. 133, 333-340. 
[11] Julius, D., Livclli, T., Jc~sel, T.M. arm Ax¢l, g. (1989) Scieng¢ 
244, 10fi7-1062. 
[12] Allen, L.F., Lcfkowitz, RJ., Caron, M.G. and Coteeehia, S. 
(1991) Prec. Natl. Aead. Sei. USA 88, 11354-11358. 
[13] Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Prec. Natl. 
Acad. flci. USA 74, $463-5467. 
[14] Tatro, J.B. and Reichlin, S. (1987) Endocrinology 121, 1900- 
1907. 
[15] Kozak, M. (1989) J. Cell Biol. 108, 229-241. 
[ 16] Kenaelly, P.J. and Krebs, E.G. (1991 ) J. Biol. Chin. 266, 15555- 
15558. 
[17] O'Dowd, B., Hnatowich, M., Caron, M.G., Le~owitz, R.J. and 
Bouvier, M. 0989) J. Biol. Chem. 264, 7564-7S69. 
[18] Sanahara, R.K., Niznik, H.B., Weiner, D.M., Stormann, T.M., 
Brann, M.R., Kennedy, J.L., Gelemter, J,E,, Rozmahol, g., 
Yang, Y., Israel, Y., $eeraan, P. and O'Dowd, B.F. (1990) Nature 
3:,7, 80-83. 
[19] Harrison, J.K., Pearson, W.R, and Lynch) K.R. (1991) Trends 
Pharmacol. Sci. 12, 62-67. 
[20] $iegrist, W., Solca, F., Stutz, $., Giuffm, K., Carrel, S., Girard, 
.1. and Ebcrlc, A.E. (1989) Cancer ges. 49, 6352-6358. 
[21] Uhler, M. and H,~rbert, E. (1983) J. Biol. Chem. 258, 257-261. 
[22] Kyte, J. and Doolittle, R.F. 0982) J. Mol. Biol. 157, 105-132. 
420 
